IMRT Combined With Lobaplatin-based CCRT in Nasopharyngeal Carcinoma
Intensity-modulated Radiotherapy Combined With Lobaplatin-based Concurrent Chemotherapy in the Treatment of Elderly Patients With Nasopharyngeal Carcinoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Lobaplatin, as a third-generation platinum-based chemotherapeutic agent, demonstrates equivalent therapeutic efficacy to cisplatin but significantly lower toxicity. Preliminary clinical trials have confirmed that lobaplatin shows substantial effectiveness in treating various cancers including breast cancer, esophageal cancer, colorectal cancer, and cervical cancer. Importantly, lobaplatin does not exhibit cross-resistance with cisplatin or carboplatin, indicating a promising application prospect.
Currently, lobaplatin has demonstrated clear efficacy in non-elderly nasopharyngeal carcinoma (NPC) chemotherapy. Guo Xiang et al. have confirmed that for non-elderly NPC patients, induction chemotherapy with lobaplatin followed by concurrent chemoradiotherapy may be a treatment option for locally advanced NPC. However, there is very limited research reporting on the use of lobaplatin in elderly NPC patients.
Based on the above theoretical considerations and our research results, lobaplatin shows good safety and reliable efficacy in treating elderly NPC, with minimal gastrointestinal reactions and low incidence of renal, neurotoxic, and ototoxic effects. This approach significantly enhances the quality of life for locally advanced elderly NPC patients. Therefore, the efficacy and safety of lobaplatin in concurrent chemotherapy for elderly NPC deserve further investigation. This study aims to evaluate the recent efficacy, safety, and toxic side effects of lobaplatin combined with intensity-modulated radiotherapy in the treatment of elderly NPC. Designed as a multicenter, open-label, prospective study, it aims to verify whether lobaplatin is an effective concurrent chemotherapeutic agent for elderly NPC, while further improving the quality of life for these patients under guarantees of therapeutic efficacy.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Fujian
-
Xiamen, Fujian, China, 361003
- The First Affiliated Hospital Of Xiamen University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Pathologically confirmed differentiated non-keratinizing carcinoma and undifferentiated non-keratinizing carcinoma;
- Stage II-IVa (UICC 8th edition);
- Acceptable induction chemotherapy and Tarceva targeted therapy;
- No history of other malignant tumors;
- Male or female, aged 65-80 years.
- Liver function: Total bilirubin ≤ Upper Limit of Normal (ULN); AST and ALT ≤ 2.5 times ULN; Alkaline phosphatase ≤ 5 times ULN;
- Renal function: Creatinine clearance ≥ 60 ml/min or Creatinine ≤ 1.5 × ULN;
- Hematological tests: Absolute Neutrophil Count (ANC) ≥ 2 × 10^9/L, Platelet count ≥ 100 × 10^9/L, and Hemoglobin ≥ 9 g/dL;
- No severe dysfunction of vital organs such as heart and lung;
- PS score ≤ 2 points
Exclusion Criteria:
- Distant metastases detected before treatment;
- Refusal to sign the informed consent form;
- Patients who cannot comply with regular follow-up due to psychological, social, family, or geographical reasons;
- Simultaneously receiving other experimental treatments in clinical trials (during the treatment phase of clinical research);
- Severe, uncontrolled infections or medical conditions;
- Vital organ dysfunction, decompensated heart, lung, kidney, or liver failure, unable to tolerate radiotherapy and chemotherapy;
- Laboratory tests: Total bilirubin > Upper Limit of Normal (ULN); AST and/or ALT > 1.5 times ULN with alkaline phosphatase > 2.5 times ULN;
- Factors affecting drug administration, distribution, metabolism, and excretion, such as mental abnormalities, central nervous system abnormalities, chronic diarrhea, ascites, pleural effusion, etc.;
- Long-term use of immunosuppressants after organ transplantation;
- Patients with a history of other malignant tumors before enrollment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Experimental
in the treatment of elderly patients with nasopharyngeal carcinoma
|
IMRT combined with two cycles of lobaplatin-based concurrent chemotherapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
objective response rate (ORR)
Time Frame: 6 months
|
ORR encompasses both CR and PR.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Safety
Time Frame: 3 months
|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
|
3 months
|
|
Overall survival (OS)
Time Frame: 3 years
|
OS was defined as the time of NPC diagnosis until death from any cause.
|
3 years
|
|
Locoregional relapse-free survival (LRFS)
Time Frame: 3 years
|
LRFS was measured as the duration time from the diagnosis of nasopharyngeal carcinoma to the occurrence of relapse in the nasopharynx or neck lymph nodes or until the last follow-up.
|
3 years
|
|
Distant metastasis-free survival (DMFS)
Time Frame: 3 years
|
DMFS was defined as the duration time of nasopharyngeal carcinoma diagnosis to the time of distant metastasis or the last follow-up.
|
3 years
|
|
Progression-free survival (PFS)
Time Frame: 3 years
|
PFS was referred to as the time from nasopharyngeal carcinoma diagnosis to the date of disease progression.
|
3 years
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Stomatognathic Diseases
- Neoplasms by Site
- Neoplasms
- Neoplasms by Histologic Type
- Head and Neck Neoplasms
- Neoplasms, Glandular and Epithelial
- Carcinoma
- Otorhinolaryngologic Diseases
- Pharyngeal Neoplasms
- Otorhinolaryngologic Neoplasms
- Nasopharyngeal Diseases
- Pharyngeal Diseases
- Nasopharyngeal Carcinoma
- Nasopharyngeal Neoplasms
Other Study ID Numbers
- 2022-KY062
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.